chr1:226548392:> Detail (hg19)

Go to:

Summary
Information
Links
Disease area statistics
MGeND
ClinVar
CIViC
DisGeNET
Annotation
Genome browser

Information

Genome

Assembly	Position
hg19	chr1:226,548,392-226,595,801
hg38	chr1:226,360,691-226,408,100

HGVS

RefSeq

Type	Transcript	Protein

Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics	Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star	[No Data.]
Show details

Links

Disease area statistics

[No Data.]

MGeND

[No Data.]

ClinVar

[No Data.]

CIViC

[No Data.]

DisGeNET

Score	Disease name	Description	Source	Pubmed	Links
0.003	squamous cell carcinoma	NA	BeFree,GAD		Detail
<0.001	Carcinoma, Transitional Cell	Biomarker-driven evaluation of PARP inhibitors in UC is justified as the activit...	BeFree	24714082	Detail
<0.001	CNS disorder	NA	BeFree		Detail
<0.001	cerebral infarction	NA	BeFree		Detail
0.120	brain ischemia	NA	BeFree,CTD_human		Detail
0.080	Transient ischemic attack	NA	RGD		Detail
<0.001	Malignant tumor of cervix	NA	BeFree		Detail
<0.001	chondrosarcoma	NA	BeFree		Detail
<0.001	Congenital chromosomal disease	Here, we report that RAD51C-deficient cells can be targeted by a 'synthetic leth...	BeFree	25292178	Detail
0.002	Cocarcinogenesis	NA	GAD		Detail
<0.001	colitis	In TNBS-induced mouse colitis models, we observed the up-regulation of VPS4B was...	BeFree	25533544	Detail
<0.001	colitis	In DSS-induced colitis mouse models, we observed the up-regulation of ESE1/ELF3 ...	BeFree	25926267	Detail
<0.001	Colonic Neoplasms	In colon tumors the PARP-1 mRNA level was higher than in unaffected colon tissue...	BeFree	25526641	Detail
0.005	Colorectal Neoplasms	NA	GAD		Detail
<0.001	Coronary Arteriosclerosis	PARP-1 and RNF146 degradation occurs in the early phase of myocardial ischemia-r...	BeFree	24842055	Detail
<0.001	Presenile dementia	NA	BeFree		Detail
0.120	dermatitis	The inhibition of PARP‑1 reduces the activity of numerous pro‑inflammatory trans...	BeFree,CTD_human	25482287	Detail
0.002	Diabetes	NA	BeFree		Detail
0.002	diabetes mellitus	NA	BeFree		Detail
0.002	Diabetes Mellitus, Insulin-Dependent	NA	GAD		Detail
0.006	Diabetes Mellitus, Non-Insulin-Dependent	eNOS 894G > T and PARP-1 Val762Ala polymorphisms appeared to associate significa...	BeFree,GAD	25041504	Detail
<0.001	Diabetic Nephropathy	eNOS 894G > T and PARP-1 Val762Ala polymorphisms appeared to associate significa...	BeFree	25041504	Detail
0.005	Diabetic Neuropathies	NA	BeFree,GAD,LHGDN		Detail
0.002	DNA Damage	NA	GAD		Detail
<0.001	Down syndrome	NA	BeFree		Detail
<0.001	Muscular Dystrophy, Duchenne	NA	BeFree		Detail
<0.001	Eosinophilia	NA	BeFree		Detail
<0.001	Esophageal Neoplasms	NA	BeFree		Detail
0.005	Fanconi anemia	Since the Fanconi anemia (FA) pathway coordinates several DNA repair pathways, i...	BeFree,LHGDN	25583207	Detail
0.005	Fanconi anemia	Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Se...	BeFree,LHGDN	25609062	Detail
0.004	glioblastoma	We previously demonstrated that robust TMZ-sensitizing effects of the [poly (ADP...	BeFree	24838527	Detail
0.004	glioblastoma	PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.	BeFree	25531448	Detail
0.011	Glioma	CQ in combination with TMZ significantly increased the amounts of LC3B-II (a mar...	BeFree,GAD,LHGDN	25434381	Detail
0.011	Glioma	PARP targeting counteracts gliomagenesis through induction of mitotic catastroph...	BeFree,GAD,LHGDN	25576921	Detail
0.002	glomerulonephritis	NA	GAD		Detail
0.002	Graft-vs-Host Disease	NA	GAD		Detail
0.003	Cardiomegaly	NA	LHGDN		Detail
<0.001	Heart failure	NA	BeFree		Detail
<0.001	congestive heart failure	NA	BeFree		Detail
<0.001	Helminthiasis	NA	BeFree		Detail
0.120	hepatitis	NA	BeFree,CTD_human		Detail
<0.001	hepatitis A	NA	BeFree		Detail
<0.001	hepatitis B	NA	BeFree		Detail
<0.001	hepatitis C	Furthermore, TRAIL enhanced PARP cleavage in apoptotic response induced by HCV i...	BeFree	24927176	Detail
<0.001	Herpes Simplex Infections	NA	BeFree		Detail
<0.001	HIV Infections	NA	BeFree		Detail
<0.001	hyperglycemia	NA	BeFree		Detail
<0.001	Hypertensive disease	Multiple logistic regression analysis revealed a significant and independent ass...	BeFree	25041504	Detail
<0.001	Immune System Diseases	NA	BeFree		Detail
0.125	Inflammation	NA	CTD_human,LHGDN		Detail
0.011	colorectal cancer	We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar...	BeFree	18006925	Detail
0.003	Malignant tumor of colon	We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar...	BeFree	18006925	Detail
0.003	colon carcinoma	We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar...	BeFree	18006925	Detail
0.003	colorectal carcinoma	We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar...	BeFree	18006925	Detail
<0.001	Rectal Carcinoma	We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar...	BeFree	18006925	Detail
0.003	ischemia	NA	BeFree		Detail
<0.001	keratoconus	Neither the g.46438521G>C polymorphism of the Nei endonuclease VIII-like 1 (NEIL...	BeFree	25356504	Detail
0.120	Kidney Diseases	NA	CTD_human		Detail
<0.001	Kidney Failure, Acute	NA	BeFree		Detail
0.120	Kyphosis deformity of spine	NA	CTD_human		Detail
0.088	Fibroid Tumor	NA	LHGDN,RGD		Detail
<0.001	leiomyosarcoma	NA	BeFree		Detail
0.005	leukemia	This study, for the first time, demonstrates that the TK target c-MYC plays a ro...	BeFree,LHGDN	25828893	Detail
0.004	chronic lymphocytic leukemia	PARP1-driven apoptosis in chronic lymphocytic leukemia.	BeFree,GAD	25161998	Detail
0.004	chronic lymphocytic leukemia	The blockade of apoptosis in co-cultured CLL cells is associated with diminution...	BeFree,GAD	25499217	Detail
<0.001	lymphoid leukemia	NA	BeFree		Detail
<0.001	Acute lymphocytic leukemia	NA	BeFree		Detail
<0.001	Leukemia, Lymphocytic, Acute, L1	NA	BeFree		Detail
0.002	Leukemia, Myelocytic, Acute	BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response...	BeFree	25483710	Detail
0.003	myeloid leukemia	NA	BeFree,GAD		Detail
0.001	Myeloid Leukemia, Chronic	This study, for the first time, demonstrates that the TK target c-MYC plays a ro...	BeFree	25828893	Detail
0.001	Myeloid Leukemia, Chronic	The current study demonstrated that treatment of CML cells with 4-MU led to indu...	BeFree	26408682	Detail
<0.001	Adult T-Cell Lymphoma/Leukemia	NA	BeFree		Detail
<0.001	leukopenia	NA	BeFree		Detail
0.001	Liver neoplasms	Human liver tumor (J5) cells were incubated with α-PA and analyzed for cell cycl...	BeFree	25077527	Detail
0.005	Chronic Obstructive Airway Disease	NA	BeFree,GAD,LHGDN		Detail
<0.001	Lung Neoplasms	NA	BeFree		Detail
0.003	Lupus Vulgaris	NA	BeFree,GAD		Detail
0.003	Lupus Erythematosus, Discoid	NA	BeFree,GAD		Detail
0.005	Lupus Erythematosus, Systemic	In this study, we report significant downregulation of HSP27 in anti-ENA(+) pati...	BeFree,GAD	25655337	Detail
0.002	Lymphatic Metastasis	NA	GAD		Detail
0.001	lymphoma	NA	BeFree		Detail
0.005	Lymphoma, Non-Hodgkin	NA	BeFree,GAD		Detail
0.003	Malignant neoplasm of stomach	Second, we choose the human gastric cancer cell lines MKN 45 as the target cell,...	BeFree	25371568	Detail
0.080	Mammary Neoplasms, Experimental	NA	RGD		Detail
<0.001	mastocytosis	NA	BeFree		Detail
0.125	melanoma	Cytotoxicity assays revealed that melanoma cell lines are very sensitive to LY20...	BeFree,GAD,GWASCAT	25915038	Detail
0.002	Meniere disease	NA	GAD		Detail
0.002	Meningeal Neoplasms	NA	GAD		Detail
0.002	meningioma	NA	GAD		Detail
<0.001	meningitis	NA	BeFree		Detail
0.002	Meningococcal Infections	NA	GAD		Detail
<0.001	Metabolic Diseases	Special attention will be laid on discussing linkage of PARP enzymes with tumor ...	BeFree	26091343	Detail
0.122	multiple myeloma	Therefore, we suggest that PARP inhibitors may deserve future investigations as ...	BeFree,CTD_human	25351371	Detail
0.003	multiple sclerosis	NA	BeFree,GAD		Detail
<0.001	muscular dystrophy	NA	BeFree		Detail
0.003	myocardial infarction	NA	BeFree,LHGDN		Detail
0.004	Neoplasm Metastasis	NA	BeFree,LHGDN		Detail
0.002	Neoplasms, Germ Cell and Embryonal	NA	GAD		Detail
0.002	Neoplasms, Radiation-Induced	NA	GAD		Detail
<0.001	nephritis	NA	BeFree		Detail
<0.001	nervous system disorder	NA	BeFree		Detail
0.001	neuroblastoma	Neuroblastoma cells demonstrated sensitivity to PARP1 inhibition (PARPi) that pa...	BeFree	25563294	Detail
0.003	acoustic neuroma	NA	BeFree,GAD		Detail
<0.001	neutropenia	NA	BeFree		Detail
<0.001	Nevus	Four SNPs were significantly associated with increasing (IRF4) or decreasing (PA...	BeFree	25307738	Detail
<0.001	Melanocytic nevus	Four SNPs were significantly associated with increasing (IRF4) or decreasing (PA...	BeFree	25307738	Detail
0.004	Non-small cell lung carcinoma	We used TaqMan to genotype four SNPs (APE1 Asp148Glu, PARP1 Va1762Ala, XRCC1 Arg...	BeFree	23479135	Detail
0.120	obesity	NA	BeFree,CTD_human		Detail
<0.001	Degenerative polyarthritis	NA	BeFree		Detail
0.001	osteosarcoma	NA	BeFree		Detail
0.002	otitis media	NA	GAD		Detail
0.018	ovarian carcinoma	The discovery of the BRCA mutation and its role in ovarian cancer and the clinic...	BeFree	24727989	Detail
0.018	ovarian carcinoma	With the exception of the role of germ-line and possibly somatic BRCA1 and BRCA2...	BeFree	24857070	Detail
0.018	ovarian carcinoma	PARP inhibition and synthetic lethality in ovarian cancer.	BeFree	24984781	Detail
0.018	ovarian carcinoma	Although at least one study to explore the use of the LOH scar in a prospective ...	BeFree	25093514	Detail
0.018	ovarian carcinoma	Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical tr...	BeFree	25292178	Detail
0.018	ovarian carcinoma	Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germ...	BeFree	25366685	Detail
0.018	ovarian carcinoma	Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ova...	BeFree	25437005	Detail
0.018	ovarian carcinoma	Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors ...	BeFree	25473022	Detail
0.018	ovarian carcinoma	These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-...	BeFree	25490527	Detail
0.018	ovarian carcinoma	In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted exp...	BeFree	25725131	Detail
0.018	ovarian carcinoma	Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian...	BeFree	25757679	Detail
0.018	ovarian carcinoma	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cance...	BeFree	25991068	Detail
0.018	ovarian carcinoma	These features of BMOC are attributed to homologous-recombination repair (HR) de...	BeFree	25993149	Detail
0.018	ovarian carcinoma	We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the ...	BeFree	25995442	Detail
0.008	Parkinson disease	NA	GAD,LHGDN		Detail
<0.001	Peyronie Disease	We observed that Ad-HDAC2 shRNA decreased inflammatory cell infiltration, reduce...	BeFree	24841412	Detail
<0.001	Peyronie Disease	Overexpression of the SMAD7 gene decreased the expression of cyclin D1 (a positi...	BeFree	25532569	Detail
0.120	Peripheral neuropathy	NA	CTD_human		Detail
<0.001	plasmacytoma	NA	BeFree		Detail
0.120	pneumonia	NA	BeFree,CTD_human		Detail
<0.001	Adenomatous Polyposis Coli	NA	BeFree		Detail
<0.001	polyps	PARP-1 and OGG1 proteins level was several fold higher in polyps and CRC in comp...	BeFree	25526641	Detail
0.003	Precancerous Conditions	IC50 values measured by sulforhodamine B (SRB) assay at 72 h and apoptosis assay...	BeFree,GAD	25917567	Detail
<0.001	Preleukemia	NA	BeFree		Detail
0.121	Prostatic Neoplasms	Pathological assessment of prostate tumors revealed that TRAMP+/-, PARP-1-/- mic...	BeFree,CTD_human	25173886	Detail
0.080	Reperfusion Injury	NA	RGD		Detail
<0.001	retinal degeneration	NA	BeFree		Detail
<0.001	rhabdomyosarcoma	NA	BeFree		Detail
<0.001	Septicemia	NA	BeFree		Detail
0.002	Skin Neoplasms	NA	GAD		Detail
0.120	Stevens-Johnson syndrome	NA	CTD_human		Detail
0.005	Stomach Neoplasms	NA	GAD		Detail
0.004	Cerebrovascular accident	NA	BeFree,LHGDN		Detail
0.002	Sunburn	NA	GAD		Detail
0.002	Thyroid Neoplasm	NA	GAD		Detail
<0.001	trigeminal neuralgia	NA	BeFree		Detail
<0.001	Chagas disease	NA	BeFree		Detail
<0.001	urticaria pigmentosa	NA	BeFree		Detail
0.120	Vitamin A Deficiency	NA	CTD_human		Detail
<0.001	vitiligo	NA	BeFree		Detail
0.003	Werner syndrome	NA	LHGDN		Detail
0.005	Helicobacter Infections	NA	GAD		Detail
<0.001	Ichthyosis, X-Linked	NA	BeFree		Detail
<0.001	B-Cell Lymphomas	Induction of apoptosis was determined by quantitation of expression level of B c...	BeFree	25142231	Detail
<0.001	High Grade Lymphoma (neoplasm)	NA	BeFree		Detail
<0.001	Familial benign pemphigus	This was followed by real-time and western blotting for ATP2C1, caspase 3, and P...	BeFree	25658765	Detail
<0.001	severe combined immunodeficiency	NA	BeFree		Detail
<0.001	Central Nervous System Neoplasms	NA	BeFree		Detail
<0.001	Polyendocrinopathies, Autoimmune	NA	BeFree		Detail
<0.001	Meningitis, Bacterial	In recent papers published by our group, we described the associations between t...	BeFree	26316174	Detail
<0.001	Synovial Cyst	NA	BeFree		Detail
<0.001	Small cell carcinoma of lung	NA	BeFree		Detail
<0.001	Myocardial Ischemia	PARP-1 and RNF146 degradation occurs in the early phase of myocardial ischemia-r...	BeFree	24842055	Detail
<0.001	Cutaneous Melanoma	NA	BeFree		Detail
<0.001	esophageal carcinoma	NA	BeFree		Detail
<0.001	Idiopathic pulmonary hypertension	Furthermore, using a gain and loss of function approach, we showed that increase...	BeFree	26084306	Detail
<0.001	Malignant neoplasm of gallbladder	NA	BeFree		Detail
<0.001	Malignant tumor of peritoneum	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib i...	BeFree	25818403	Detail
<0.001	acute myocardial infarction	NA	BeFree		Detail
<0.001	Disease of capillaries	NA	BeFree		Detail
<0.001	Tumor Progression	Together, these results suggest that Lnc_bc060912, via PARP1 and NPM1, affects c...	BeFree	25848691	Detail
<0.001	Germ cell tumor	NA	BeFree		Detail
<0.001	HIV Encephalopathy	NA	BeFree		Detail
<0.001	embryonal carcinoma	NA	BeFree		Detail
<0.001	teratocarcinoma	NA	BeFree		Detail
<0.001	Comedone	NA	BeFree		Detail
<0.001	Memory impairment	NA	BeFree		Detail
<0.001	gallbladder carcinoma	NA	BeFree		Detail
<0.001	Zinc deficiency	NA	BeFree		Detail
0.004	pancreatic carcinoma	PARP-inhibitors in BRCA-associated pancreatic cancer.	BeFree	25076338	Detail
0.004	pancreatic carcinoma	Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic can...	BeFree	25117293	Detail
0.004	pancreatic carcinoma	Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase c...	BeFree	25333575	Detail
0.004	pancreatic carcinoma	Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer...	BeFree	25864590	Detail
<0.001	Testicular embryonal carcinoma	NA	BeFree		Detail
0.002	age related macular degeneration	NA	GAD		Detail
0.120	Parkinsonian Disorders	NA	CTD_human		Detail
<0.001	Sepsis	NA	BeFree		Detail
<0.001	Acute respiratory failure	NA	BeFree		Detail
<0.001	Diabetic Polyneuropathies	NA	BeFree		Detail
<0.001	Coinfection	NA	BeFree		Detail
<0.001	HIV encephalitis	NA	BeFree		Detail
<0.001	Carcinoma breast stage IV	NA	BeFree		Detail
0.001	Ovarian epithelial cancer recurrent	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurren...	BeFree	26303225	Detail
<0.001	Small cell lung cancer limited stage	Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in...	BeFree	25400754	Detail
<0.001	Metastatic melanoma	NA	BeFree		Detail
<0.001	Cancer of Head and Neck	Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.	BeFree	25017803	Detail
<0.001	Cancer of Head and Neck	Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Se...	BeFree	25609062	Detail
<0.001	Liver and Intrahepatic Biliary Tract Carcinoma	The aim of this preclinical study was to evaluate the expression of PARP and PAR...	BeFree	25139788	Detail
<0.001	Squamous cell carcinoma of esophagus	NA	BeFree		Detail
<0.001	Adenocarcinoma Of Esophagus	NA	BeFree		Detail
0.002	Solid tumour	Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated pol...	BeFree	25483710	Detail
0.002	Solid tumour	PARP inhibitors have gained recent attention as promising therapeutic agents for...	BeFree	25528020	Detail
0.002	Solid tumour	Olaparib (Lynparza™) is an oral, small molecule, poly (ADP-ribose) polymerase in...	BeFree	25616434	Detail
0.002	Solid tumour	Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biolo...	BeFree	25757679	Detail
0.002	Solid tumour	Cytotoxicity assays revealed that melanoma cell lines are very sensitive to LY20...	BeFree	25915038	Detail
<0.001	stage, ovarian epithelial cancer	The purpose of this review will be to discuss PARP inhibition in advanced stage ...	BeFree	24984781	Detail
<0.001	secondary acute myeloid leukemia	NA	BeFree		Detail
<0.001	Adenocarcinoma of pancreas	NA	BeFree		Detail
0.001	cervix carcinoma	NA	BeFree		Detail
<0.001	Dermatitis verrucosa	In vitro siRNA RET/PTC3 showed significant (p<0.001) inhibitory effects on RP3 c...	BeFree	24759995	Detail
<0.001	Tumor necrosis	NA	BeFree		Detail
<0.001	pilocytic astrocytoma	NA	BeFree		Detail
0.001	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	NA	BeFree		Detail
<0.001	Acute retention of urine	NA	BeFree		Detail
<0.001	African Burkitt's lymphoma	NA	BeFree		Detail
<0.001	Malignant neoplasm of liver	The aim of this preclinical study was to evaluate the expression of PARP and PAR...	BeFree	25139788	Detail
<0.001	malignant mesothelioma	NA	BeFree		Detail
0.002	Breast Cancer, Familial	Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a p...	BeFree	24962108	Detail
0.002	Breast Cancer, Familial	Here, we use a genetically engineered mouse model of BRCA2-associated hereditary...	BeFree	25511378	Detail
0.004	Malignant neoplasm of pancreas	PARP-inhibitors in BRCA-associated pancreatic cancer.	BeFree	25076338	Detail
0.004	Malignant neoplasm of pancreas	Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic can...	BeFree	25117293	Detail
0.004	Malignant neoplasm of pancreas	Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase c...	BeFree	25333575	Detail
0.004	Malignant neoplasm of pancreas	Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer...	BeFree	25864590	Detail
<0.001	skin papilloma	NA	BeFree		Detail
0.010	Malignant neoplasm of prostate	We identified differential therapeutic vulnerabilities that emerge upon the loss...	BeFree,GAD	24866151	Detail
0.010	Malignant neoplasm of prostate	Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and P...	BeFree,GAD	25127709	Detail
0.010	Malignant neoplasm of prostate	Defining the EMT control by PARP-1 during prostate cancer progression is of tran...	BeFree,GAD	25173886	Detail
0.010	Malignant neoplasm of prostate	Due to the heterogeneity of prostate cancer, the combination of several biomarke...	BeFree,GAD	25485532	Detail
0.010	Malignant neoplasm of prostate	In a phase II study, researchers found that the PARP inhibitor olaparib led to s...	BeFree,GAD	25583815	Detail
0.010	Malignant neoplasm of prostate	In addition, it was recently shown that aberrations in DNA repair genes, such as...	BeFree,GAD	26210103	Detail
<0.001	Nijmegen breakage syndrome	NA	BeFree		Detail
0.003	Chronic Kidney Insufficiency	NA	BeFree,GAD		Detail
0.006	lupus erythematosus	NA	BeFree,GAD		Detail
<0.001	Primary antiphospholipid syndrome	NA	BeFree		Detail
0.001	endometrial carcinoma	Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitr...	BeFree	24927325	Detail
<0.001	dyslexia	NA	BeFree		Detail
<0.001	dementia	NA	BeFree		Detail
0.080	Necrotizing Enterocolitis	NA	RGD		Detail
<0.001	Recurrent tumor	NA	BeFree		Detail
<0.001	Allergic encephalitis	NA	BeFree		Detail
0.003	Malignant neoplasm of esophagus	NA	BeFree,GAD		Detail
<0.001	Thyroid carcinoma	NA	BeFree		Detail
<0.001	Ewings sarcoma	NA	BeFree		Detail
<0.001	Malignant glioma	NA	BeFree		Detail
0.001	Osteosarcoma of bone	NA	BeFree		Detail
0.005	Carcinogenesis	We further show that superactivation of the prosurvival PI3K-AKT signaling pathw...	BeFree	24866151	Detail
0.005	Carcinogenesis	PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenes...	BeFree	25173886	Detail
0.007	prostate carcinoma	We identified differential therapeutic vulnerabilities that emerge upon the loss...	BeFree	24866151	Detail
0.007	prostate carcinoma	Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and P...	BeFree	25127709	Detail
0.007	prostate carcinoma	Defining the EMT control by PARP-1 during prostate cancer progression is of tran...	BeFree	25173886	Detail
0.007	prostate carcinoma	Due to the heterogeneity of prostate cancer, the combination of several biomarke...	BeFree	25485532	Detail
0.007	prostate carcinoma	In a phase II study, researchers found that the PARP inhibitor olaparib led to s...	BeFree	25583815	Detail
0.007	prostate carcinoma	In addition, it was recently shown that aberrations in DNA repair genes, such as...	BeFree	26210103	Detail
<0.001	Hereditary Breast and Ovarian Cancer Syndrome	NA	BeFree		Detail
0.005	Epithelial ovarian cancer	A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP...	BeFree,GAD	25634215	Detail
0.005	Epithelial ovarian cancer	Loss of HR accounts for the genomic instability of EOCs and for their cellular h...	BeFree,GAD	25642963	Detail
0.005	Epithelial ovarian cancer	Women with histologically proven EOC who were randomised to treatment groups in ...	BeFree,GAD	25991068	Detail
0.023	breast carcinoma	Drug repurposing screen identifies lestaurtinib amplifies the ability of the pol...	BeFree	24962108	Detail
0.023	breast carcinoma	Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensiti...	BeFree	24970803	Detail
0.023	breast carcinoma	Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recomb...	BeFree	25085902	Detail
0.023	breast carcinoma	TGFβ induces BRCAness and sensitivity to PARP inhibition in breast cancer by reg...	BeFree	25103497	Detail
0.023	breast carcinoma	We developed an assay for measuring PARP activity in cell lysates and found that...	BeFree	25199834	Detail
0.023	breast carcinoma	Since the development of first-generation PARP inhibitors more than a decade ago...	BeFree	25286972	Detail
0.023	breast carcinoma	LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no...	BeFree	25333773	Detail
0.023	breast carcinoma	The identification of new molecular biomarkers that would allow the rapid identi...	BeFree	25416589	Detail
0.023	breast carcinoma	A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast can...	BeFree	25485588	Detail
0.023	breast carcinoma	We demonstrated that NAM reduces PARP activity in vitro, and in cells subjected ...	BeFree	25504347	Detail
0.023	breast carcinoma	Biological and clinical significance of PARP1 protein expression in breast cance...	BeFree	25528020	Detail
0.023	breast carcinoma	Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells a...	BeFree	25677620	Detail
0.023	breast carcinoma	This phenomenon is also observed in in vitro models of basal-like breast cancer,...	BeFree	25679396	Detail
0.023	breast carcinoma	When BRCA1/2 BCs were compared to triple-negative (TN) sporadic tumours of the s...	BeFree	25690937	Detail
0.023	breast carcinoma	HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.	BeFree	25769025	Detail
0.023	breast carcinoma	Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important ...	BeFree	25796377	Detail
0.023	breast carcinoma	Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibi...	BeFree	25812606	Detail
0.023	breast carcinoma	PARP1 and phospho-p65 protein expression is increased in human HER2-positive bre...	BeFree	25833211	Detail
0.023	breast carcinoma	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-d...	BeFree	26100884	Detail
0.023	breast carcinoma	Noteworthy, long-term treatment with DHADA and EPADA caused the blockade of auto...	BeFree	26272430	Detail
0.003	colon carcinoma	This suggests reciprocal influence of PARP-1 and OGG1 on their expression and st...	BeFree	25526641	Detail
0.003	colon carcinoma	Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell...	BeFree	25738796	Detail
0.003	stomach carcinoma	Second, we choose the human gastric cancer cell lines MKN 45 as the target cell,...	BeFree	25371568	Detail
<0.001	Carcinoma of bladder	NA	BeFree		Detail
0.001	Central neuroblastoma	Neuroblastoma cells demonstrated sensitivity to PARP1 inhibition (PARPi) that pa...	BeFree	25563294	Detail
<0.001	Cockayne Syndrome, Type II	NA	BeFree		Detail
<0.001	Mitochondrial Diseases	Recent studies report that increased availability of intracellular NAD obtained ...	BeFree	25788480	Detail
<0.001	lymphangioleiomyomatosis	NA	BeFree		Detail
<0.001	Adenomatous polyp of colon	PARP-1 expression is increased in colon adenoma and carcinoma and correlates wit...	BeFree	25526641	Detail
<0.001	Helicobacter pylori infection	NA	BeFree		Detail
<0.001	Invasive breast carcinoma	NA	BeFree		Detail
<0.001	Precursor B-lymphoblastic lymphoma/leukemia	NA	BeFree		Detail
<0.001	Chronic graft-versus-host disease	NA	BeFree		Detail
<0.001	Enzyme inhibition disorder	These features of BMOC are attributed to homologous-recombination repair (HR) de...	BeFree	25993149	Detail
<0.001	Pelvic Organ Prolapse	NA	BeFree		Detail
<0.001	Asthma chronic	To increase the clinical significance of our studies, it is imperative to demons...	BeFree	26205779	Detail
0.120	Cardiomyopathies	NA	CTD_human		Detail
<0.001	Cerebral Ischemia	NA	BeFree		Detail
<0.001	ovarian neoplasm	NA	BeFree		Detail
<0.001	Renal ischaemia	NA	BeFree		Detail
<0.001	Metastatic Prostate Carcinoma	NA	BeFree		Detail
<0.001	precancerous lesions	NA	BeFree		Detail
<0.001	West Nile viral infection	NA	BeFree		Detail
<0.001	Monoclonal Gammapathies	NA	BeFree		Detail
0.017	Malignant neoplasm of ovary	The discovery of the BRCA mutation and its role in ovarian cancer and the clinic...	BeFree	24727989	Detail
0.017	Malignant neoplasm of ovary	With the exception of the role of germ-line and possibly somatic BRCA1 and BRCA2...	BeFree	24857070	Detail
0.017	Malignant neoplasm of ovary	PARP inhibition and synthetic lethality in ovarian cancer.	BeFree	24984781	Detail
0.017	Malignant neoplasm of ovary	Although at least one study to explore the use of the LOH scar in a prospective ...	BeFree	25093514	Detail
0.017	Malignant neoplasm of ovary	Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical tr...	BeFree	25292178	Detail
0.017	Malignant neoplasm of ovary	Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germ...	BeFree	25366685	Detail
0.017	Malignant neoplasm of ovary	Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ova...	BeFree	25437005	Detail
0.017	Malignant neoplasm of ovary	Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors ...	BeFree	25473022	Detail
0.017	Malignant neoplasm of ovary	These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-...	BeFree	25490527	Detail
0.017	Malignant neoplasm of ovary	In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted exp...	BeFree	25725131	Detail
0.017	Malignant neoplasm of ovary	Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian...	BeFree	25757679	Detail
0.017	Malignant neoplasm of ovary	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cance...	BeFree	25991068	Detail
0.017	Malignant neoplasm of ovary	These features of BMOC are attributed to homologous-recombination repair (HR) de...	BeFree	25993149	Detail
0.017	Malignant neoplasm of ovary	We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the ...	BeFree	25995442	Detail
<0.001	Squamous cell carcinoma of the head and neck	The observed reliance upon PARP-mediated mechanisms reveals a means by which Fan...	BeFree	25609062	Detail
<0.001	Intestinal Polyposis	NA	BeFree		Detail
<0.001	Myxoid cyst	NA	BeFree		Detail
0.004	sarcoma	NA	BeFree,LHGDN		Detail
<0.001	large cell medulloblastoma	NA	BeFree		Detail
<0.001	Precursor B-cell lymphoblastic leukemia	NA	BeFree		Detail
<0.001	Adenoma of large intestine	NA	BeFree		Detail
<0.001	Eosinophilic disorder	NA	BeFree		Detail
<0.001	Hormone refractory prostate cancer	NA	BeFree		Detail
<0.001	Aggressive Non-Hodgkin Lymphoma	NA	BeFree		Detail
<0.001	Hereditary Malignant Neoplasm	This review article will discuss (1) the BRCA1 and BRCA2 genes within the larger...	BeFree	25725131	Detail
<0.001	Metaplastic breast carcinoma	As BRCA1 deficiency sensitizes tumors to DNA cross-linking agents and poly(ADP-r...	BeFree	26100884	Detail
0.001	pancreatic ductal adenocarcinoma	Erlotinib+gemcitabine-treated PDAC(CBL-low) cells exhibited greater apoptosis by...	BeFree	25348515	Detail
0.001	pancreatic ductal adenocarcinoma	BRCA2-associated pancreatic ductal adenocarcinoma (PDAC) may be sensitive to age...	BeFree	25864590	Detail
<0.001	Sporadic Breast Carcinoma	These findings enable better selection of patients with sporadic breast cancer f...	BeFree	25103497	Detail
<0.001	Sporadic Breast Carcinoma	Our findings indicate that nPARP1 expression is an independent factor for sporad...	BeFree	26205471	Detail
<0.001	differentiated thyroid gland carcinoma	NA	BeFree		Detail
<0.001	Benign melanocytic nevus	Four SNPs were significantly associated with increasing (IRF4) or decreasing (PA...	BeFree	25307738	Detail
0.127	Mammary Neoplasms	Functional ex vivo assay to select homologous recombination-deficient breast tum...	BeFree,CTD_human,LHGDN	24963051	Detail
<0.001	Mammary Tumorigenesis	NA	BeFree		Detail
<0.001	Skin Carcinogenesis	NA	BeFree		Detail
<0.001	Tumor Angiogenesis	NA	BeFree		Detail
0.001	Xenograft Model	6MP was identified in a screen for novel drugs and found to selectively kill BRC...	BeFree	25526776	Detail
<0.001	Rash and Dermatitis Adverse Event Associated with Chemoradiation	NA	BeFree		Detail
0.080	Renal Insufficiency	NA	RGD		Detail
<0.001	Glioblastoma multiforme	In this study we dissected the action of PARP inhibition in different GBM cell l...	BeFree	25576921	Detail
<0.001	Disorder characterized by eosinophilia	NA	BeFree		Detail
<0.001	Classic medulloblastoma	NA	BeFree		Detail
<0.001	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)	NA	BeFree		Detail
0.001	uterine corpus cancer	Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitr...	BeFree	24927325	Detail
<0.001	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	NA	BeFree		Detail
<0.001	Precursor Cell Lymphoblastic Leukemia Lymphoma	NA	BeFree		Detail
<0.001	Photoreceptor degeneration	NA	BeFree		Detail
<0.001	Urothelial Carcinoma	Biomarker-driven evaluation of PARP inhibitors in UC is justified as the activit...	BeFree	24714082	Detail
0.006	liver carcinoma	In contrast, here we demonstrated apoptosis induction in human lung epithelial c...	BeFree,LHGDN	24918927	Detail
0.006	liver carcinoma	Infection of Ad5/F35-XAF1 induced cleavage of caspase -3, -8, -9 and PARP in HCC...	BeFree,LHGDN	24980821	Detail
0.006	liver carcinoma	PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 i...	BeFree,LHGDN	25139788	Detail
0.006	liver carcinoma	PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells v...	BeFree,LHGDN	25499136	Detail
0.006	liver carcinoma	Compared with the sole use of each agent, PHA-767491 in combination with 5-FU ex...	BeFree,LHGDN	25643258	Detail
0.120	Ceroid lipofuscinosis, neuronal 1, infantile	NA	CTD_human		Detail
<0.001	Nasopharyngeal carcinoma	NA	BeFree		Detail
0.120	Plaque, Atherosclerotic	NA	CTD_human		Detail
0.080	Neointima	NA	RGD		Detail
<0.001	Pulmonary arterial hypertension	Furthermore, using a gain and loss of function approach, we showed that increase...	BeFree	26084306	Detail
<0.001	Early-Stage Breast Carcinoma	To test this hypothesis, we investigated 1406 ER(+) early-stage breast cancers w...	BeFree	25111287	Detail
<0.001	Warsaw breakage syndrome	Lymphoblastoid cell lines derived from individuals with FA or clinically related...	BeFree	25583207	Detail
0.002	Solar Erythema	NA	GAD		Detail
<0.001	myelodysplastic syndrome	NA	BeFree		Detail
0.002	FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)	Since the Fanconi anemia (FA) pathway coordinates several DNA repair pathways, i...	BeFree	25583207	Detail
0.002	FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)	Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Se...	BeFree	25609062	Detail
<0.001	Severe dementia	NA	BeFree		Detail
0.007	Triple Negative Breast Neoplasms	Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic letha...	BeFree	25026298	Detail
0.007	Triple Negative Breast Neoplasms	Discovery of the molecular signalling molecules that define TNBC heterogeneity h...	BeFree	25456381	Detail
0.007	Triple Negative Breast Neoplasms	Germ-line mutations may occur in up to 20% of unselected patients with TNBC, whi...	BeFree	25881743	Detail
0.007	Triple Negative Breast Neoplasms	Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances ...	BeFree	25888415	Detail
0.003	Infection	NA	LHGDN		Detail
0.120	intellectual disability	NA	CTD_human		Detail
<0.001	Pulmonary hypertension, primary, 1, with hereditary hemorrhagic telangiectasia	Furthermore, using a gain and loss of function approach, we showed that increase...	BeFree	26084306	Detail
<0.001	High grade serous carcinoma	NA	BeFree		Detail
<0.001	adenoma	NA	BeFree		Detail
0.120	alopecia	NA	CTD_human		Detail
0.006	Alzheimer's disease	Variants of Base Excision Repair Genes MUTYH , PARP1 and XRCC1 in Alzheimer's Di...	BeFree,GAD	25998844	Detail
0.006	amyotrophic lateral sclerosis	NA	BeFree,LHGDN		Detail
0.120	anemia	NA	CTD_human		Detail
0.003	Angina, Unstable	NA	BeFree,LHGDN		Detail
<0.001	anthrax disease	Moreover, delivery of MCFVv into host cells either as a fusion to the N-terminal...	BeFree	26351282	Detail
0.003	arthritis	NA	BeFree,GAD		Detail
0.010	rheumatoid arthritis	NA	BeFree,GAD,LHGDN		Detail
0.124	asthma	PARP is activated in human asthma and its inhibition by olaparib blocks house du...	BeFree,CTD_human,GAD	26205779	Detail
<0.001	ataxia telangiectasia	NA	BeFree		Detail
0.120	atherosclerosis	NA	BeFree,CTD_human		Detail
<0.001	Autoimmune Diseases	NA	BeFree		Detail
0.004	Non-small cell lung carcinoma	We genotyped SNPs of ADPRT (rs1136410 [V762A]), XRCC1 (rs1799782 [R194W], rs2548...	BeFree	21420246	Detail
<0.001	Rash and Dermatitis Adverse Event Associated with Chemoradiation	We genotyped SNPs of ADPRT (rs1136410 [V762A]), XRCC1 (rs1799782 [R194W], rs2548...	BeFree	21420246	Detail
0.006	Malignant neoplasm of urinary bladder	NA	BeFree,GAD		Detail
<0.001	Bloom syndrome	NA	BeFree		Detail
<0.001	Bone neoplasms	NA	BeFree		Detail
0.080	borna disease	NA	RGD		Detail
0.005	Brain Neoplasms	NA	GAD		Detail
0.027	Malignant neoplasm of breast	Drug repurposing screen identifies lestaurtinib amplifies the ability of the pol...	BeFree,GAD	24962108	Detail
0.027	Malignant neoplasm of breast	Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensiti...	BeFree,GAD	24970803	Detail
0.027	Malignant neoplasm of breast	Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recomb...	BeFree,GAD	25085902	Detail
0.027	Malignant neoplasm of breast	TGFβ induces BRCAness and sensitivity to PARP inhibition in breast cancer by reg...	BeFree,GAD	25103497	Detail
0.027	Malignant neoplasm of breast	We developed an assay for measuring PARP activity in cell lysates and found that...	BeFree,GAD	25199834	Detail
0.027	Malignant neoplasm of breast	Since the development of first-generation PARP inhibitors more than a decade ago...	BeFree,GAD	25286972	Detail
0.027	Malignant neoplasm of breast	LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no...	BeFree,GAD	25333773	Detail
0.027	Malignant neoplasm of breast	The identification of new molecular biomarkers that would allow the rapid identi...	BeFree,GAD	25416589	Detail
0.027	Malignant neoplasm of breast	A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast can...	BeFree,GAD	25485588	Detail
0.027	Malignant neoplasm of breast	We demonstrated that NAM reduces PARP activity in vitro, and in cells subjected ...	BeFree,GAD	25504347	Detail
0.027	Malignant neoplasm of breast	Biological and clinical significance of PARP1 protein expression in breast cance...	BeFree,GAD	25528020	Detail
0.027	Malignant neoplasm of breast	Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells a...	BeFree,GAD	25677620	Detail
0.027	Malignant neoplasm of breast	This phenomenon is also observed in in vitro models of basal-like breast cancer,...	BeFree,GAD	25679396	Detail
0.027	Malignant neoplasm of breast	When BRCA1/2 BCs were compared to triple-negative (TN) sporadic tumours of the s...	BeFree,GAD	25690937	Detail
0.027	Malignant neoplasm of breast	HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.	BeFree,GAD	25769025	Detail
0.027	Malignant neoplasm of breast	Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important ...	BeFree,GAD	25796377	Detail
0.027	Malignant neoplasm of breast	Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibi...	BeFree,GAD	25812606	Detail
0.027	Malignant neoplasm of breast	PARP1 and phospho-p65 protein expression is increased in human HER2-positive bre...	BeFree,GAD	25833211	Detail
0.027	Malignant neoplasm of breast	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-d...	BeFree,GAD	26100884	Detail
0.027	Malignant neoplasm of breast	Noteworthy, long-term treatment with DHADA and EPADA caused the blockade of auto...	BeFree,GAD	26272430	Detail
<0.001	bronchopneumonia	NA	BeFree		Detail
<0.001	Burkitt lymphoma	NA	BeFree		Detail
0.003	Malignant tumor of colon	This suggests reciprocal influence of PARP-1 and OGG1 on their expression and st...	BeFree	25526641	Detail
0.003	Malignant tumor of colon	Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell...	BeFree	25738796	Detail
0.001	Malignant neoplasm of endometrium	Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitr...	BeFree	24927325	Detail
<0.001	Rectal Carcinoma	NA	BeFree		Detail
<0.001	Malignant neoplasm of thyroid	NA	BeFree		Detail
0.002	basal cell carcinoma	NA	GAD		Detail
<0.001	Noninfiltrating Intraductal Carcinoma	NA	BeFree		Detail
<0.001	Merkel cell carcinoma	Furthermore, we identified 365 proteins (including 326 novel MCC-interactors) in...	BeFree	25200342	Detail
0.004	Non-small cell lung carcinoma	PARP inhibitors: an interesting pathway also for non-small cell lung cancer?	BeFree	24191958	Detail
0.004	Non-small cell lung carcinoma	CCDC6 could represent a predictive biomarker of resistance to conventional singl...	BeFree	25302833	Detail
<0.001	renal cell carcinoma	NA	BeFree		Detail
<0.001	vitiligo	We found that a significantly increased risk of vitiligo was associated with the...	BeFree	23369758	Detail
0.003	stomach carcinoma	ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in ...	BeFree	22901183	Detail
<0.001	Small cell carcinoma of esophagus	We retrospectively examined whether there was an association between the selecte...	BeFree	25374063	Detail
0.011	Glioma	Interestingly, the risk for glioma was dramatically increased in ionizing radiat...	BeFree	19124499	Detail
0.003	Malignant neoplasm of stomach	ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in ...	BeFree	22901183	Detail
<0.001	VITILIGO-ASSOCIATED MULTIPLE AUTOIMMUNE DISEASE SUSCEPTIBILITY 1 (finding)	We found that a significantly increased risk of vitiligo was associated with the...	BeFree	23369758	Detail

Annotation

Annotations

Descrption	Source	Links
NA	DisGeNET	Detail
Biomarker-driven evaluation of PARP inhibitors in UC is justified as the activity of CEP-9722 correl...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Here, we report that RAD51C-deficient cells can be targeted by a 'synthetic lethal' approach using P...	DisGeNET	Detail
NA	DisGeNET	Detail
In TNBS-induced mouse colitis models, we observed the up-regulation of VPS4B was accompanied with th...	DisGeNET	Detail
In DSS-induced colitis mouse models, we observed the up-regulation of ESE1/ELF3 accompanied with the...	DisGeNET	Detail
In colon tumors the PARP-1 mRNA level was higher than in unaffected colon tissue and in polyp tissue...	DisGeNET	Detail
NA	DisGeNET	Detail
PARP-1 and RNF146 degradation occurs in the early phase of myocardial ischemia-reperfusion injury; i...	DisGeNET	Detail
NA	DisGeNET	Detail
The inhibition of PARP‑1 reduces the activity of numerous pro‑inflammatory transcription factors, wh...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
eNOS 894G > T and PARP-1 Val762Ala polymorphisms appeared to associate significantly with DN, with t...	DisGeNET	Detail
eNOS 894G > T and PARP-1 Val762Ala polymorphisms appeared to associate significantly with DN, with t...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Since the Fanconi anemia (FA) pathway coordinates several DNA repair pathways, including homologous ...	DisGeNET	Detail
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi...	DisGeNET	Detail
We previously demonstrated that robust TMZ-sensitizing effects of the [poly (ADP-ribose) polymerase]...	DisGeNET	Detail
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.	DisGeNET	Detail
CQ in combination with TMZ significantly increased the amounts of LC3B-II (a marker for autophagosom...	DisGeNET	Detail
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Furthermore, TRAIL enhanced PARP cleavage in apoptotic response induced by HCV infection, indicating...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Multiple logistic regression analysis revealed a significant and independent association of eNOS 894...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo...	DisGeNET	Detail
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo...	DisGeNET	Detail
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo...	DisGeNET	Detail
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo...	DisGeNET	Detail
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo...	DisGeNET	Detail
NA	DisGeNET	Detail
Neither the g.46438521G>C polymorphism of the Nei endonuclease VIII-like 1 (NEIL1) nor the c.2285T>C...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
This study, for the first time, demonstrates that the TK target c-MYC plays a role in transcriptiona...	DisGeNET	Detail
PARP1-driven apoptosis in chronic lymphocytic leukemia.	DisGeNET	Detail
The blockade of apoptosis in co-cultured CLL cells is associated with diminution in caspase-3 and PA...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibit...	DisGeNET	Detail
NA	DisGeNET	Detail
This study, for the first time, demonstrates that the TK target c-MYC plays a role in transcriptiona...	DisGeNET	Detail
The current study demonstrated that treatment of CML cells with 4-MU led to induction of apoptosis t...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Human liver tumor (J5) cells were incubated with α-PA and analyzed for cell cycle distribution, expr...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
In this study, we report significant downregulation of HSP27 in anti-ENA(+) patients and increased e...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Second, we choose the human gastric cancer cell lines MKN 45 as the target cell, which was co-cultur...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Cytotoxicity assays revealed that melanoma cell lines are very sensitive to LY2090314 in vitro (IC50...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Special attention will be laid on discussing linkage of PARP enzymes with tumor biology, oxidative s...	DisGeNET	Detail
Therefore, we suggest that PARP inhibitors may deserve future investigations as tools for medical tr...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Neuroblastoma cells demonstrated sensitivity to PARP1 inhibition (PARPi) that paralleled PARP1 expre...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Four SNPs were significantly associated with increasing (IRF4) or decreasing (PARP1, CDK6 and PLA2G6...	DisGeNET	Detail
Four SNPs were significantly associated with increasing (IRF4) or decreasing (PARP1, CDK6 and PLA2G6...	DisGeNET	Detail
We used TaqMan to genotype four SNPs (APE1 Asp148Glu, PARP1 Va1762Ala, XRCC1 Arg194Trp and XRCC1 Arg...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
The discovery of the BRCA mutation and its role in ovarian cancer and the clinical application of th...	DisGeNET	Detail
With the exception of the role of germ-line and possibly somatic BRCA1 and BRCA2 mutations and their...	DisGeNET	Detail
PARP inhibition and synthetic lethality in ovarian cancer.	DisGeNET	Detail
Although at least one study to explore the use of the LOH scar in a prospective clinical trial of a ...	DisGeNET	Detail
Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical trials for the treatme...	DisGeNET	Detail
Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2...	DisGeNET	Detail
Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ovarian cancers that ha...	DisGeNET	Detail
Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigat...	DisGeNET	Detail
These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-deficient ovarian ca...	DisGeNET	Detail
In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by t...	DisGeNET	Detail
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.	DisGeNET	Detail
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.	DisGeNET	Detail
These features of BMOC are attributed to homologous-recombination repair (HR) deficiency in the abse...	DisGeNET	Detail
We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on...	DisGeNET	Detail
NA	DisGeNET	Detail
We observed that Ad-HDAC2 shRNA decreased inflammatory cell infiltration, reduced transnuclear expre...	DisGeNET	Detail
Overexpression of the SMAD7 gene decreased the expression of cyclin D1 (a positive cell cycle regula...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
PARP-1 and OGG1 proteins level was several fold higher in polyps and CRC in comparison to normal col...	DisGeNET	Detail
IC50 values measured by sulforhodamine B (SRB) assay at 72 h and apoptosis assays (annexin V stainin...	DisGeNET	Detail
NA	DisGeNET	Detail
Pathological assessment of prostate tumors revealed that TRAMP+/-, PARP-1-/- mice exhibited higher g...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Induction of apoptosis was determined by quantitation of expression level of B cell lymphoma 2 (Bcl-...	DisGeNET	Detail
NA	DisGeNET	Detail
This was followed by real-time and western blotting for ATP2C1, caspase 3, and PARP proteins to exam...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
In recent papers published by our group, we described the associations between the single nucleotide...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
PARP-1 and RNF146 degradation occurs in the early phase of myocardial ischemia-reperfusion injury; i...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Furthermore, using a gain and loss of function approach, we showed that increased hypoxia-inducible ...	DisGeNET	Detail
NA	DisGeNET	Detail
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of p...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Together, these results suggest that Lnc_bc060912, via PARP1 and NPM1, affects cell apoptosis and ma...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
PARP-inhibitors in BRCA-associated pancreatic cancer.	DisGeNET	Detail
Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.	DisGeNET	Detail
Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pan...	DisGeNET	Detail
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-rib...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a ...	DisGeNET	Detail
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small...	DisGeNET	Detail
NA	DisGeNET	Detail
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.	DisGeNET	Detail
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi...	DisGeNET	Detail
The aim of this preclinical study was to evaluate the expression of PARP and PARG genes in a panel o...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Olaparib (AZD-2281, Ku-0059436) is an orally bioavailable and well-tolerated poly(ADP-ribose) polyme...	DisGeNET	Detail
PARP inhibitors have gained recent attention as promising therapeutic agents for the treatment of so...	DisGeNET	Detail
Olaparib (Lynparza™) is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor being develo...	DisGeNET	Detail
Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovar...	DisGeNET	Detail
Cytotoxicity assays revealed that melanoma cell lines are very sensitive to LY2090314 in vitro (IC50...	DisGeNET	Detail
The purpose of this review will be to discuss PARP inhibition in advanced stage ovarian cancer, high...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
In vitro siRNA RET/PTC3 showed significant (p<0.001) inhibitory effects on RP3 cell viability (MTT a...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
The aim of this preclinical study was to evaluate the expression of PARP and PARG genes in a panel o...	DisGeNET	Detail
NA	DisGeNET	Detail
Poly (ADP-ribose) polymerase 1 (PARP1) inhibitor (PARPi)-mediated therapy is a promising approach fo...	DisGeNET	Detail
Here, we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to st...	DisGeNET	Detail
PARP-inhibitors in BRCA-associated pancreatic cancer.	DisGeNET	Detail
Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.	DisGeNET	Detail
Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pan...	DisGeNET	Detail
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-rib...	DisGeNET	Detail
NA	DisGeNET	Detail
We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p5...	DisGeNET	Detail
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.	DisGeNET	Detail
Defining the EMT control by PARP-1 during prostate cancer progression is of translational significan...	DisGeNET	Detail
Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to a...	DisGeNET	Detail
In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tum...	DisGeNET	Detail
In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are ...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
We further show that superactivation of the prosurvival PI3K-AKT signaling pathway limits the effica...	DisGeNET	Detail
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.	DisGeNET	Detail
We identified differential therapeutic vulnerabilities that emerge upon the loss of both PTEN and p5...	DisGeNET	Detail
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.	DisGeNET	Detail
Defining the EMT control by PARP-1 during prostate cancer progression is of translational significan...	DisGeNET	Detail
Due to the heterogeneity of prostate cancer, the combination of several biomarkers is necessary to a...	DisGeNET	Detail
In a phase II study, researchers found that the PARP inhibitor olaparib led to stable disease or tum...	DisGeNET	Detail
In addition, it was recently shown that aberrations in DNA repair genes, such as BRCA2 and ATM, are ...	DisGeNET	Detail
NA	DisGeNET	Detail
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistanc...	DisGeNET	Detail
Loss of HR accounts for the genomic instability of EOCs and for their cellular hyper-dependence on a...	DisGeNET	Detail
Women with histologically proven EOC who were randomised to treatment groups in trials that either c...	DisGeNET	Detail
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polym...	DisGeNET	Detail
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and b...	DisGeNET	Detail
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast ca...	DisGeNET	Detail
TGFβ induces BRCAness and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair g...	DisGeNET	Detail
We developed an assay for measuring PARP activity in cell lysates and found that the basal activity ...	DisGeNET	Detail
Since the development of first-generation PARP inhibitors more than a decade ago, numerous clinical ...	DisGeNET	Detail
LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no effect on non-tumor...	DisGeNET	Detail
The identification of new molecular biomarkers that would allow the rapid identification of BC prese...	DisGeNET	Detail
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.	DisGeNET	Detail
We demonstrated that NAM reduces PARP activity in vitro, and in cells subjected or not to DNA damage...	DisGeNET	Detail
Biological and clinical significance of PARP1 protein expression in breast cancer.	DisGeNET	Detail
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic s...	DisGeNET	Detail
This phenomenon is also observed in in vitro models of basal-like breast cancer, and is associated w...	DisGeNET	Detail
When BRCA1/2 BCs were compared to triple-negative (TN) sporadic tumours of the studied DDR proteins,...	DisGeNET	Detail
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.	DisGeNET	Detail
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important group of promising d...	DisGeNET	Detail
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expres...	DisGeNET	Detail
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.	DisGeNET	Detail
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic...	DisGeNET	Detail
Noteworthy, long-term treatment with DHADA and EPADA caused the blockade of autophagic flux followed...	DisGeNET	Detail
This suggests reciprocal influence of PARP-1 and OGG1 on their expression and stability, and may con...	DisGeNET	Detail
Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest throug...	DisGeNET	Detail
Second, we choose the human gastric cancer cell lines MKN 45 as the target cell, which was co-cultur...	DisGeNET	Detail
NA	DisGeNET	Detail
Neuroblastoma cells demonstrated sensitivity to PARP1 inhibition (PARPi) that paralleled PARP1 expre...	DisGeNET	Detail
NA	DisGeNET	Detail
Recent studies report that increased availability of intracellular NAD obtained by inhibition of the...	DisGeNET	Detail
NA	DisGeNET	Detail
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
These features of BMOC are attributed to homologous-recombination repair (HR) deficiency in the abse...	DisGeNET	Detail
NA	DisGeNET	Detail
To increase the clinical significance of our studies, it is imperative to demonstrate that PARP is a...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
The discovery of the BRCA mutation and its role in ovarian cancer and the clinical application of th...	DisGeNET	Detail
With the exception of the role of germ-line and possibly somatic BRCA1 and BRCA2 mutations and their...	DisGeNET	Detail
PARP inhibition and synthetic lethality in ovarian cancer.	DisGeNET	Detail
Although at least one study to explore the use of the LOH scar in a prospective clinical trial of a ...	DisGeNET	Detail
Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical trials for the treatme...	DisGeNET	Detail
Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2...	DisGeNET	Detail
Detecting mutation in BRCA1/2 is a generally accepted strategy for screening ovarian cancers that ha...	DisGeNET	Detail
Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigat...	DisGeNET	Detail
These studies have prompted the use of PARP inhibitors to treat BRCA1 and BRCA2-deficient ovarian ca...	DisGeNET	Detail
In December 2014, a poly(ADP-ribose) polymerase (PARP) inhibitor was granted expedited approved by t...	DisGeNET	Detail
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.	DisGeNET	Detail
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.	DisGeNET	Detail
These features of BMOC are attributed to homologous-recombination repair (HR) deficiency in the abse...	DisGeNET	Detail
We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on...	DisGeNET	Detail
The observed reliance upon PARP-mediated mechanisms reveals a means by which Fanconi anemia HNSCCs c...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
This review article will discuss (1) the BRCA1 and BRCA2 genes within the larger context of homologo...	DisGeNET	Detail
As BRCA1 deficiency sensitizes tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (P...	DisGeNET	Detail
Erlotinib+gemcitabine-treated PDAC(CBL-low) cells exhibited greater apoptosis by cleaved PARP, caspa...	DisGeNET	Detail
BRCA2-associated pancreatic ductal adenocarcinoma (PDAC) may be sensitive to agents that target homo...	DisGeNET	Detail
These findings enable better selection of patients with sporadic breast cancer for PARP intervention...	DisGeNET	Detail
Our findings indicate that nPARP1 expression is an independent factor for sporadic BCs and PARP1 inh...	DisGeNET	Detail
NA	DisGeNET	Detail
Four SNPs were significantly associated with increasing (IRF4) or decreasing (PARP1, CDK6 and PLA2G6...	DisGeNET	Detail
Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibit...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
6MP was identified in a screen for novel drugs and found to selectively kill BRCA-defective cells in...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
In this study we dissected the action of PARP inhibition in different GBM cell lines with either fun...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Biomarker-driven evaluation of PARP inhibitors in UC is justified as the activity of CEP-9722 correl...	DisGeNET	Detail
In contrast, here we demonstrated apoptosis induction in human lung epithelial carcinoma (A549), hum...	DisGeNET	Detail
Infection of Ad5/F35-XAF1 induced cleavage of caspase -3, -8, -9 and PARP in HCC cells.	DisGeNET	Detail
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocel...	DisGeNET	Detail
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/...	DisGeNET	Detail
Compared with the sole use of each agent, PHA-767491 in combination with 5-FU exhibited much stronge...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Furthermore, using a gain and loss of function approach, we showed that increased hypoxia-inducible ...	DisGeNET	Detail
To test this hypothesis, we investigated 1406 ER(+) early-stage breast cancers with 20 years' long-t...	DisGeNET	Detail
Lymphoblastoid cell lines derived from individuals with FA or clinically related syndromes, such as ...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Since the Fanconi anemia (FA) pathway coordinates several DNA repair pathways, including homologous ...	DisGeNET	Detail
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi...	DisGeNET	Detail
NA	DisGeNET	Detail
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhib...	DisGeNET	Detail
Discovery of the molecular signalling molecules that define TNBC heterogeneity has led to the develo...	DisGeNET	Detail
Germ-line mutations may occur in up to 20% of unselected patients with TNBC, which may serve as a bi...	DisGeNET	Detail
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects o...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Furthermore, using a gain and loss of function approach, we showed that increased hypoxia-inducible ...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Variants of Base Excision Repair Genes MUTYH , PARP1 and XRCC1 in Alzheimer's Disease Risk.	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Moreover, delivery of MCFVv into host cells either as a fusion to the N-terminal fragment of anthrax...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced dise...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
We genotyped SNPs of ADPRT (rs1136410 [V762A]), XRCC1 (rs1799782 [R194W], rs25489 [R280H], and rs254...	DisGeNET	Detail
We genotyped SNPs of ADPRT (rs1136410 [V762A]), XRCC1 (rs1799782 [R194W], rs25489 [R280H], and rs254...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polym...	DisGeNET	Detail
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and b...	DisGeNET	Detail
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast ca...	DisGeNET	Detail
TGFβ induces BRCAness and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair g...	DisGeNET	Detail
We developed an assay for measuring PARP activity in cell lysates and found that the basal activity ...	DisGeNET	Detail
Since the development of first-generation PARP inhibitors more than a decade ago, numerous clinical ...	DisGeNET	Detail
LCS101 was also found to induce PARP-1 reduction in breast cancer cells, with no effect on non-tumor...	DisGeNET	Detail
The identification of new molecular biomarkers that would allow the rapid identification of BC prese...	DisGeNET	Detail
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.	DisGeNET	Detail
We demonstrated that NAM reduces PARP activity in vitro, and in cells subjected or not to DNA damage...	DisGeNET	Detail
Biological and clinical significance of PARP1 protein expression in breast cancer.	DisGeNET	Detail
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic s...	DisGeNET	Detail
This phenomenon is also observed in in vitro models of basal-like breast cancer, and is associated w...	DisGeNET	Detail
When BRCA1/2 BCs were compared to triple-negative (TN) sporadic tumours of the studied DDR proteins,...	DisGeNET	Detail
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.	DisGeNET	Detail
Poly(ADP-ribose) polymerase inhibitors (PARP inhibitors) represent an important group of promising d...	DisGeNET	Detail
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expres...	DisGeNET	Detail
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.	DisGeNET	Detail
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic...	DisGeNET	Detail
Noteworthy, long-term treatment with DHADA and EPADA caused the blockade of autophagic flux followed...	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
This suggests reciprocal influence of PARP-1 and OGG1 on their expression and stability, and may con...	DisGeNET	Detail
Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest throug...	DisGeNET	Detail
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
NA	DisGeNET	Detail
Furthermore, we identified 365 proteins (including 326 novel MCC-interactors) in the MCC interactome...	DisGeNET	Detail
PARP inhibitors: an interesting pathway also for non-small cell lung cancer?	DisGeNET	Detail
CCDC6 could represent a predictive biomarker of resistance to conventional single mode therapy and y...	DisGeNET	Detail
NA	DisGeNET	Detail
We found that a significantly increased risk of vitiligo was associated with the APE1 Asp/Glu (adjus...	DisGeNET	Detail
ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in Sichuan of China.	DisGeNET	Detail
We retrospectively examined whether there was an association between the selected six single nucleot...	DisGeNET	Detail
Interestingly, the risk for glioma was dramatically increased in ionizing radiation exposure individ...	DisGeNET	Detail
ADPRT Val762Ala and XRCC1 Arg194Trp polymorphisms and risk of gastric cancer in Sichuan of China.	DisGeNET	Detail
We found that a significantly increased risk of vitiligo was associated with the APE1 Asp/Glu (adjus...	DisGeNET	Detail

Overlapped Transcript Coordinates

Gene	Transcript ID	Exon Number	Chromosome	Start	Stop	Type	Amino Mutation	Transcript Position	Links

Overlapped Transcript

Gene	Transcript ID	Chromosome	Start	Stop	Links

Gene: -
dbSNP: rs386493716 dbSNP
Genome: hg19
Position: chr1:226,548,392-226,595,801
Variant Type: snv

Genome browser